system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
Exhibit 10.1 Certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed. Information that has been omitted has been noted in this document with a placeholder identified by the mark "[***]". EXECUTION COPY PROMOTION AGREEMENT by and between SIGA TECHNOLOGIES, INC. and MERIDIAN MEDICAL TECHNOLOGIES, INC., a Pfizer company Source: SIGA TECHNOLOGIES INC, 8-K, 6/3/2019 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 ARTICLE 2 GRANT OF RIGHTS 11 2.1 Grant of Rights to MMT 11 2.2 Negative Covenants 11 2.3 Non-Compete Covenant 11 2.4 Retained Rights 12 2.5 No Implied Licenses 12 2.6 [***] 12 ARTICLE 3 GOVERNANCE 12 3.1 Joint Steering Committee 12 3.2 Good Faith 12 3.3 Scope of Governance 13 ARTICLE 4 PROMOTION AND OTHER COMMERCIALIZATION 13 4.1 Promotion in the Territory 13 4.2 Diligence 14 4.3 Customer Contracts 14 4.4 Regulatory Matters 15 4.5 Discontinued Countries 15 ARTICLE 5 FORECASTING AND ORDERING 15 5.1 Product Forecasts 15 5.2 Purchase Orders 15 5.3 Delivery 16 5.4 Supply Limitation 16 5.5 Supply Penalties 16 5.6 Adverse Event Reporting 16 ARTICLE 6 PAYMENTS 16 6.1 Promotion Fee 16 6.2 Payments 17 6.3 Currency 17 6.4 Records 17 6.5 Audits 18 6.6 Blocked Payment and Indemnification 19 6.7 Source of Recovery 19 6.8 Taxes 19 ARTICLE 7 INTELLECTUAL PROPERTY 20 7.1 Ownership of SIGA Intellectual Property 20 7.2 Intellectual Property Maintenance 20 7.3 New Patents and Trademarks 20 -i- Source: SIGA TECHNOLOGIES INC, 8-K, 6/3/2019 TABLE OF CONTENTS (CONTINUED) PAGE ARTICLE 8 REPRESENTATIONS AND WARRANTIES; COVENANTS 21 8.1 Mutual Representations and Warranties 21 8.2 Additional Representations, Warranties and Covenants of SIGA 22 8.3 Additional Representations and Warranties of MMT 26 8.4 Covenants 27 8.5 No Other Representations or Warranties 29 ARTICLE 9 INDEMNIFICATION 29 9.1 Indemnification by SIGA 29 9.2 Indemnification by MMT 30 9.3 Indemnification Procedures 30 9.4 Insurance 31 9.5 Limitation of Liability 31 ARTICLE 10 CONFIDENTIALITY 31 10.1 Confidentiality 31 10.2 Authorized Disclosure 32 10.3 Technical Publication 33 10.4 Publicity; Terms of Agreement 33 10.5 Prior Confidentiality Agreements 34 10.6 Return of Confidential Information 34 10.7 Unauthorized Use 34 10.8 Exclusive Property 34 ARTICLE 11 TERM AND TERMINATION 35 11.1 Term 35 11.2 Termination for Cause 35 11.3 Termination Upon Certain Changes of Control 36 11.4 Termination for Failure to [***] 36 11.5 Termination for Convenience 36 11.6 Effect of Termination 36 11.7 Survival 36 ARTICLE 12 DISPUTE RESOLUTION 36 12.1 Executive Officer Resolution 36 12.2 Governing Law 37 12.3 Jurisdiction 37 12.4 NO JURY TRIAL 37 ARTICLE 13 MISCELLANEOUS 38 13.1 Entire Agreement; Amendment 38 13.2 Force Majeure 38 -ii- Source: SIGA TECHNOLOGIES INC, 8-K, 6/3/2019 TABLE OF CONTENTS (CONTINUED) PAGE 13.3 Notices 38 13.4 No Strict Construction; Interpretation; Headings 39 13.5 Assignment 40 13.6 Performance by Affiliates 40 13.7 Further Assurances and Actions 40 13.8 Severability 41 13.9 No Waiver 41 13.10 Relationship of the Parties 41 13.11 English Language 42 13.12 Counterparts 42 13.13 Schedules 42 13.14 Expenses 42 Exhibit A Permitted Subcontractors Exhibit B Business Plan Exhibit C SIGA Press Release Schedule 1 SIGA Patents Schedule 2 SIGA Trademarks Schedule 3 Safety Reporting Requirements Schedule 8.2(b) Encumbrances -iii- Source: SIGA TECHNOLOGIES INC, 8-K, 6/3/2019 PROMOTION AGREEMENT This PROMOTION AGREEMENT (this "Agreement") is entered into as of May 31, 2019 (the "Effective Date") by and between SIGA TECHNOLOGIES, INC., a Delaware corporation having an address at 31 East 62nd Street, New York, NY 10065 ("SIGA"), and MERIDIAN MEDICAL TECHNOLOGIES, INC., a Pfizer company, and Delaware corporation having an address at 6350 Stevens Forest Road, Suite #301, Columbia, MD 21046 ("MMT"). SIGA and MMT are sometimes referred to individually as a "Party" and collectively as the "Parties". RECITALS WHEREAS, SIGA developed the FDA-approved oral capsule formulation of TPOXX® (tecovirimat) for the treatment of smallpox; WHEREAS, MMT possesses resources and expertise in the marketing, promoting, advertising, offering for sale and selling of pharmaceutical and antiviral products; and WHEREAS, MMT desires to obtain from SIGA, and SIGA desires to grant to MMT certain exclusive licenses in the Territory to market, promote, advertise, offer for sale and sell the Product in the Field in the Territory, as set forth herein. NOW, THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties hereby agree as follows: ARTICLE 1 DEFINITIONS "Active Country" has the meaning set forth in Section 4.4(b). "Affiliate" means, with respect
"""

Extract the exact clause related to "Uncapped Liability" from the excerpt above.